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ABSTRACT 
 
 
 
Rizvi, Sahar. M.S., Purdue University, December 2012. Determination of the Active 
Components of Elderberry Extracts on Immune Function and Tumor Cell Growth. Major 
Professor:  Elliott Blumenthal. 
 
 
 
Present cancer treatments cause the cessation of the body’s own natural defenses, 
resulting in the susceptibility of patients to other illnesses, namely infection, during 
therapy. Contemporary research must focus on developing treatments to preserve or even 
augment the body’s natural defenses by pursuing naturally-derived elements devoid of 
such adverse effects. Seeking more natural treatments, Sambucus Nigra (elderberry) 
proves to be an important source of known immune stimulators including anthocyanins, 
catechins, and tannins, as wells as several known antioxidants and tumor suppressive 
agents in the form of flavonoids and proanthocyanidins. 
Our primary goal was to separate the distinctive components of an elderberry 
extract using gravity column chromatography and examine their proliferative effects on T 
lymphocytes as well as their inhibitory effects on the growth of human skin melanoma 
cells. 
           Due to the successful effects of crude elderberry extracts on both immune 
enhancement and tumor suppression, we concluded that there must be specific 
components within the berry that enables its therapeutic value.
xii 
 
The effects on immune cell stimulation were assessed through the quantitative 
analysis of spleen cell proliferation, which yielded significantly positive spleen cell 
stimulation following the addition of and concanavalin A, a known mitogen, as compared 
to the spleen cells incubated solely with concanavalin A.  
The inhibitory effect of the extract fractions was examined on a melanoma cell 
line. The successful suppression of tumor cell growth by several of the elderberry extract 
fractions, without mass suppression, was observed. In vivo studies using specific 
elderberry fractions may validate the use of the resolved components as viable 
therapeutic agents both in immunotherapy as well as chemotherapy. 
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INTRODUCTION 
 
Cancer 
 Cancer is a devastating illness with both somatic and emotional consequences, 
and when uncontrolled, results in rapid death, making cancer the leading cause of 
mortality in the United States, second only to cardiovascular disease. According to the 
American Cancer Society, one out of every four deaths in the United States is due to 
cancer. Furthermore, in 2010 approximately 1,529,560 new cases of cancer were 
predicted to be diagnosed, and about 569,490 Americans were expected to die of cancer 
which meant nearly 1,500 people per day. Skin cancer is the most prevalent form, with an 
estimated over 3.5 million cancers diagnosed in more than two million people in the 
United States alone. Each year there is a greater incidence of skin cancer than the 
collective incidence of breast, prostate, lung, and colon cancers. The most malignant and 
dire form of skin cancer is a melanoma. Every sixty-two minutes, a person dies from 
melanoma, and in 2010 it was estimated that approximately 11,790 deaths would occur as 
a result of skin cancer. To understand the destructive consequences of the disease it is 
important to comprehend the pathological process of the diseased tissue. Cancer is the 
accelerated production of cells that have ceased to follow their expected reproductive and 
proliferative functions. These cells may also proceed to invade adjacent tissues 
contiguous to the atypical growth, and even possibly spread to other organs in the body, 
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in a process known as metastasis. Exposure to chemical carcinogens, radiation and even 
some viruses may produce mutations in cells, resulting in unregulated growth patterns. 
Cancer cells retain the ability to become malignant through mutations in growth control 
mechanisms of cells, including proto-oncogenes and their corresponding tumor 
suppressor proteins. 
With the promising developments in clinical research and technology, the 
diagnosis and management of numerous diseases have improved significantly over time. 
The number of deaths per year related to cancer remains high, but the mortality rate has 
declined due to the progression and advancements in treatment modalities, allowing a 
greater chance of possibly surviving this morbid disease. 
 
Role of the Immune System in Tumor Detection and Elimination 
The human immune system, which contains a network of cells, tissues, and organs work 
synchronously together to defend against foreign invaders. The integrity of the immune 
system is critical in the identification and targeting of mutated cells in the body. The 
ultimate operative responsibility of the immune system is to differentiate between a “self” 
cell and a “non-self,” or foreign, cell in order to rid the body of external intruders, while 
maintaining a homeostatic balance of self cells.  This ability enables the immune cells to 
directly attack foreign cells and readily eliminate them through various immunological 
mechanisms. The immune cells are challenged when they encounter cancerous cells; by 
acting as a “self” cell, altered cells often go undetected by surveillance mechanisms 
during the initial phases of tumorigenesis. Once a tumor cell is recognized, cell growth 
can be halted through the process of necrosis or apoptosis. Necrosis is characterized by 
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mitochondrial swelling and increased permeability of the plasma membrane, while 
apoptosis is the process of programmed cell death and involves the breakdown of the cell 
into membrane-bound components that can be easily removed. 
 The immune system is categorized into two main subsets, the innate immune 
system and the acquired immune system. The innate immune system is characterized as 
the fast-acting, nonspecific portion of the immune system, comprising of the body’s 
natural barriers, phagocytes, natural killer cells, and other molecules involved in the 
stimulation of other immune responses. In the event of tumorigenesis, natural killer (NK) 
cells serve a key role in stimulating a cascade of events resulting in tumor cell death. In 
addition to the activation of other immune cells through the secretion of cytokines and 
other factors, NK cells primarily attack tumor cells through the release of the cytolytic 
protein, perforin as well as serine proteases known as granzymes. Perforin generates 
transmembrane holes in target cells that can function as channels for other defensive 
proteins to be inserted. Granzymes then invade the target cells, forcing them to undergo 
apoptosis through the activation of certain caspase molecules. The cytotoxic effects of 
natural killer cells are highly specific and generally function successfully without 
harming the normal cells.  
Acquired immunity constitutes the portion of the immune system that takes longer 
to respond and is antigen specific, and forms memory cells to act quickly in any 
subsequent exposure to the same invader. The acquired immune system further divided 
into the humoral immune response, governed by the B lymphocytes and the cell-mediated 
response, mediated by the T lymphocytes. B cells primarily release antibodies in response 
to exposure to a foreign antigen, and are successful in combating bacteria, bacterial 
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toxins, and viruses that circulate freely in body fluids, before they enter cells. T cells are 
responsible for targeting bacteria and viruses that have already invaded host cells and are 
inaccessible to antibodies, fungal infections, cancer cells, and the rejection of 
transplanted tissue. Therefore, in the defense against tumor cells, it is the cell-mediated 
immune function that engages a non-specific, nonclonal reponse in combating these 
altered cells.  
In order for the cytotoxic T (Tc) lymphocytes to take action against tumor cells, 
the abnormal cells must surface proteins present that can be recognized as foreign. These 
may be neoantigens or even alterations of existing antigens and can be formed through 
the modifications in gene expression. The Tc cells then react to tumor cells through the 
recognition of these surface antigens by triggering apoptosis through one of two 
pathways. The first pathway entails the release of granules from the cytotoxic cells that in 
turn activate the appropriate components that will induce apoptosis, while the second 
pathway involves the union of the Fas ligand on the surface of the T cell with the Fas 
surface protein on the target cell. This association leads to the activation of the enzymes 
that can trigger apoptosis through the destruction of the cytoskeleton proteins of the 
tumor cell. 
Tumors may illicit an immune response as apparent through the regression of 
residual tumors once a primary tumor is removed. The presence of tumor-specific 
antibodies and T lymphocytes in patients with tumors also confirms an active immune 
reaction opposing the propagation of malformed cells.  There is even an increased 
prevalence of malignancies in immunodeficient patients including transplant patients, 
who have increased susceptibility to Kaposi sarcoma and patients with acquired immune 
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deficiency syndrome, who have a greater propensity to Epstein Barr virus-induced 
lymphoma.  
Cancer cells employ several different methods to evade recognition and 
destruction by the immune system. Not all cancer cells possess all of the surface markers 
that are required for complete activation of the cytotoxic T cells. This could include the 
altered surface antigens, the major histocompatibility complex molecule or even the co-
stimulatory surface molecules. Absence of any one of these molecules will result in a 
lack of reactivity by the Tc cells. In addition to the physical attributes of the tumor cells, 
themselves, tumor cells have been known to release chemical substances that possess the 
ability to suppress the responses of the immune system. Melanoma cells in particular 
secrete several substances, including follistatin, placenta growth factor and vascular 
endothelial growth factor. Notably, melanoma cells secrete transforming growth factor-
beta (TGF-β), which serves an important role in immunosuppression. TGF- β has 
possesses inhibitory effects on the proliferation of thymocytes, B and T lymphocytes, 
natural killer cells, monocytes, as well as macrophages, making its release by melanoma 
cells highly detrimental to the host’s reactivity against these tumor cells.  
 
Caspase Activity 
Caspases are proteases that possess an integral role in apoptosis, by the physical 
breakdown of cellular components. Caspase regulation is the central focus in anti-cancer 
medication due to their profound impact on the apoptotic process. Even when the body 
mounts a response to carcinogenic activity, the rate of transformation of these cells and 
the production of mutated progeny considerably outweighs the defense capabilities of the 
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immune system, and therefore external assistance is mandatory in the form of different 
therapeutic regimens. There are two primary pathways to activate caspase activity. The 
first pathway, called activation-induced cell death, which is the most common pathway of 
apoptosis activation outside the thymus, involves the Fas surface protein and the Fas 
ligand and usually takes about 2-4 hours. Upon T cell activation, the expression of these 
surface proteins is up regulated by the T cell. The binding of Fas ligand to Fas causes the 
recruitment of FADD (Fas-associated protein with death domain) followed by the 
subsequent binding of procaspase 8. The association of procaspase 8 and FADD causes 
the proteolytic cleavage of procaspase 8 into its active form, caspase 8, which then 
initiates a cascading event of proteolysis and ultimately cell death. 
Another pathway used in inducing apoptosis, the mitochondrial death pathway, is 
much longer than the Fas pathway, taking up to 8-10 hours. In this pathway, cytochrome 
c, which normally inhabits in the inner mitochondrial membrane, escapes into the cytosol 
which enables it to bind to the protein Apaf-1 (apoptotic protease-activating factor I). 
This causes Apaf-1 to undergo an ATP-dependent conformational change and 
oligomerization, which enables its binding to procaspase 9 and the conversion of 
procaspase 9 to caspase 9. The complex formed here consisting of caspase 9, Apaf-1, and 
cytochrome c, is termed the apoptosome and it cleaves procaspase 3, generating the 
active form caspase 3, which leads to more events that result in apoptosis. The 
mitochondrion also releases AIF (apoptosis inducing factor) which also functions in cell 
death. 
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Current Cancer Treatment Options 
 Through several decades of research, clinical trials, and determination, cancer 
treatment has evolved from the primitive techniques of cauterizing mutated tissue to 
several curative choices in cancer intervention. Presently, the most common treatment 
options for cancer include chemotherapy, radiation therapy, surgery, and post-surgical 
pharmaceutical therapy.   
Unfortunately, the negative repercussions of these treatment modalities may, at 
times, outweigh their proposed benefits. Depending on the extent of growth and the 
locality of the tumor or tumors, surgical techniques such as cryosurgery, electrosurgery 
and laproscopic surgery are often the preliminary therapeutic approach, but may 
frequently result in bleeding, scarring, and even loss of bone tissue, which can pave way 
for further complications. Chemotherapeutic agents such as carboplatin, doxorubicin, and 
imatinib mesylate commonly induce adverse effects such as anemia, bleeding, alopecia, 
and fertility changes, while radiation therapy may cause negative symptoms like 
vomiting, physical pain, and fatigue. A common thread amongst all of these therapeutic 
agents in treating cancer is that, although they serve to target tumor cell death, they do 
not enhance the body’s own defense system. Even more detrimental to the patient, most 
therapeutic agents used in cancer treatment are immunosuppressant, which creates 
susceptibility to other illnesses during the attempt of eliminating malignant tissue. The 
most common diseases acquired by immunocompromised patients are bacterial, viral, and 
fungal infections. Prophylactic treatments are commonly used amongst cancer patients 
but involve an increase in medications required in the diet, amplifying the chance of even 
more side effects. It is highly encouraged that immunodeficient patients avoid contact 
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with others and maintain limited interaction with their close family and friends to reduce 
the risk of contracting infection. This can take a mental and physical toll on both the 
patient and the patient’s family as well.  
 
Natural Therapeutic Agents 
 With scientific advancement and the progression of cancer therapy, researchers 
must concentrate on regimens that will not disrupt the function of the patient’s immune 
system by pursuing more naturally-derived elements. A more favorable alternative would 
be to investigate an agent that would preserve or even augment the body’s natural 
defenses. Research on naturally-derived compounds such as turmeric, ginger, and a wide 
variety of spices and natural foods have confirmed the existence of therapeutic value in 
these substances. For centuries, Asian folk medicine has incorporated the benefits of 
turmeric into their herbal remedies. Now, the use of scientific investigative methods has 
confirmed the therapeutic benefits possessed by curcumin, the active ingredient in 
turmeric. The assessment of the suppression of a murine histiocytic tumor, AK-5, was 
assessed when treated with curcumin. Apoptosis analysis revealed the induction of 
typical chemical features of apoptosis including evidence of apoptotic bodies as well as 
AK-5 DNA fragmentation involving caspase-3. 80% of the animals that were 
transplanted with AK-5 cells did not develop fluid in the peritoneal cavity after the 
curcumin treatment was administered (Khar 1999).  
 Extensive studies have established the potential preventative effects of ginger root 
on noncardia gastric adenocarcinoma. The ginger root was tested on 19 different strains 
of Helicobacter pylori, several of which were of the CagA+ strain. The ability of the 
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gingerols in ginger to inhibit the growth of the CagA+ strain of H. pylori establishes its 
ability to prevent tumor manifestation in the gastric tract due to the known positive role 
of H. pylori in the development of tumors (Mahady 2003).  
 Notably, saffron has already been established as an agent suitable for its anti-
cancer effects. Furthermore, the chemoprotective role of saffron in the prevention of 
genotoxicity by known anti-tumor drugs was assessed. Saffron was administered to mice 
prior to their treatment with cisplatin, cyclophosphamide, or mitomycin C. Comet assays 
reveal the decreased DNA damage induced by the anti-tumor agents as compared to mice 
not receiving prophylactic treatment with saffron (Premkumar 2006). 
 
Sambucus Nigra 
 As researchers continue to search nature for therapies that are non-engineered, 
elderberry emerges as an essential source of several therapeutic agents. Commonly found 
in North America and Europe, elderberry’s primary use lies in wines, jams, and other 
foods for both flavor and color enhancement. For centuries, this beneficial fruit served as 
a source of medicinal therapies including treating open wounds, influenza, and even the 
common cold in European folk medicine (Balch 1990). As a homeopathic remedy, it has 
proven its effectiveness in numerous ailments and conditions such as constipation and 
rheumatism (Kilham 2001). Due to its exhibition of curative value, elderberry has ignited 
interest in its chemopreventative qualities and immune enhancement capabilities, 
therefore creating an increase in the investigative research surrounding this berry.  
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Elderberry as an Immune Modulator 
On its own, elderberry, has even displayed a significant role in immune 
modulation via the stimulation of inflammatory cytokine production (Barak 2002). 
Interleukins 1, 2, and 6 were increased following elderberry administration. Interferon γ 
and tumor necrosis factor α were also shown to be increased by elderberry, and therefore 
substantiates the role of elderberry in the augmentation of cytokine production (Burns 
2010). 
 
Elderberry as an Anti-Carcinogenic 
Elderberry was shown to serve as an inhibitory of the initiation and promotion 
stages of carcinogenesis. Both the phenolic components (quercetin, proanthocyanidins, 
etc,) and the nonphenolic compounds (sesquiterpenes, phytosterols, etc.) were active 
participants in the strong induction of quinone reductase (anti-initiation) and inhibition of 
cyclooxygenase-2 (anti-promotion).  (Thole 2006). In the combination of several 
different berry extracts known as Optiberry, elderberry and other bacciferous fruits 
proved to be powerful antioxidants and anti-carcinogens (Bagchi 2004). 
 
Elderberry as an Anti-Viral 
 The anti-influenza activity of elderberry extract was assessed in an in vitro assay, 
with human influenza A virus particles. The flavonoids in the elderberry extract prevent 
the entry of viruses into the host cell, thereby inhibiting successful viral infection 
(Roschek 2009) In a separate study, it was found that patients suffering from influenza-
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like symptoms that received 15 mL of elderberry daily, recovered an average of 4 days 
faster than patients taking a placebo (Zakay-Rones 2004). 
 
Sambucol 
Due to the beneficial effects of elderberry, a standardized extract of elderberry has 
been produced in the form of Sambucol. Studies analyzing the effects of Sambucol have 
confirmed the anti-viral effects of elderberry. Sambucol proved 99% effective against the 
H5N1 virus and even neutralized its infectivity in cell cultures (Patton 2006). In two 
separate studies, Sambucol displayed its chemotherapeutic value in the recovery from 
influenza. During an outbreak of influenza B, improvement of symptoms was seen sooner 
as compared to control groups (Zakay-Rones 1995). It decreased the duration of flu-like 
symptoms in another double-blind, placebo-controlled study (Erling 2004). 
 The therapeutic activity of elderberry is correlated with its high content of 
antioxidants and tumor suppressive agents in the form of flavonoids and 
proanthocyanidins. For a summary of the compounds found in elderberry with their 
known benefits, see Table A1. In the treatment of cancer, the goal is not only to remove 
the cancerous tissue, but to augment the body’s natural capacity to prevent and combat 
mutation in the body. As technology advances and new treatments are developed, one 
must investigate the possibilities of merging natural, immune-enhancing products with 
the innovated techniques and products. The more natural a product is, the less adverse 
effects it can have on the body.   
 Currently, experimental data has proven its role as an antiviral as well as a 
possible role in the treatment of diabetes through its ability to induce increased glucose 
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uptake by tissues, open wounds, rheumatoid arthritis, sore throat, influenza, anti-
carcinogenic, anti-angiogenic, and antioxidant, even as anti-viral. 
 In recent years, the therapeutic performance of elderberry in medicinal treatment 
has been proven against heart attacks, stroke, and even tumor cell proliferation. Based on 
these suggestions, we sought to discover the exact components of the elderberry that are 
effect against both tumor cells proliferation as well as their inductive effects on the 
immunological cells. 
 
Aim 
 The primary goal for this research endeavor was to isolate the active components 
of the elderberry extract, which result in immune enhancement and tumor suppression. 
Once these components were isolated, their proliferative effects on murine cells were 
assessed and compared to those of a known mitogen, concanavalin A (con A), which has 
displayed a proficiency in stimulating the proliferation of T lymphocytes. In addition, the 
suppressive capabilities of these components will be determined through their incubation 
with human skin melanoma cells. Whole elderberry extract maintains proliferative effects 
on spleen cells as well as suppressive capabilities on tumor cells. Therefore, it was 
hypothesized that there would be specific fractions of the extract that would enhance 
spleen cell proliferation, and specific fractions of the extract that would specifically 
suppress tumor cells. Any samples that exhibit activity will be further analyzed using 
nuclear magnetic resonance in order to identify the composition of the sample. 
13 
 
MATERIALS AND METHODS 
 
Sambucus Nigra Extract Characteristics 
 The sample used for these studies was a 13% standardized elderberry powder 
prepared by Artemis, International, Inc. Pure elderberry was concentrated without any 
solvent through physical means and spray dried onto maltodextrin (Artemis International, 
Inc. 2005). The most significant components of this standardized elderberry extract 
includes anthocyanins and polyphenols. For complete composition of Sambucus Nigra, 
see Table A1. 
 
Resolution of Elderberry Extract 
 The components of the Sambucus Nigra extract were separated utilizing column 
chromatography. The different chemical components elute off of the column based on 
their polarity and that of the eluent, and enable further analysis of the individual 
chemicals found in elderberry. Separation of the components proved to be infeasible by 
column chromatography using silica gel as the adsorbent and ethyl acetate/formic 
acid/acetic acid/water as the eluent, see Appendix C. 
 A second protocol was adapted from Strack et al., with 
poly(vinylpolypyrrolidone) (PVP) serving as the stationary phase. This polymer has been 
widely used in the separatory techniques of anthocyanins, so a finer resolution would be 
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expected. 2 g of the 13% standardized elderberry extract was dissolved in 4 mL of 0.01N 
hydrochloric acid (HCl). A 250-mL column (d ≈ 2.5 cm) was filled with 25 g of dry PVP 
(height ≈ 18.4 cm), and the prepared elderberry extract was added. The mobile phase was 
a gradient containing an increasing ratio of methanol to deionized water, and an equal 
amount of 0.01N HCl, see Appendix C. The solutions were added sequentially in order of 
descending polarity. 
 
Concentration of Resolved Samples 
 16.5-mL fractions were collected from the column (Figure B1) and stored at 4
o
C 
to maintain the integrity of the contents. For the collection times, see Table A2. Once the 
fractions were collected, the bulk of the solvent was evaporated off using a rotary 
evaporator (Figure B2a) to achieve more concentrated samples for the experimental 
analysis. The samples were concentrated down to approximately 2 mL, to ensure a 
sufficient amount for both experimental use and identification purposes. Depending on 
the percentage of methanol in the sample, the evaporation rates varied for each of the 
fractions (Table A3). 
 
Preliminary Identification through Thin Layer Chromatography 
 To obtain a finer resolution of the compounds collected through the column 
chromatography, the fractions were separated further through thin layer chromatography. 
As the stationary phase, mylar backed silica gel (JT Baker) plates were used. The plates 
were prepared by creating a base line 0.5 cm from one end of the plate as well as a 
solvent front line 0.5 cm from the other side of the plate. Each fraction was spotted 
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(diameter of the spots = 2mm) on the midpoint of the baseline of the plate using 
microcapillary tubes. A mixture of butanol, acetic acid, and deionized water (4:1:5) was 
used as the mobile phase (Hurst 2002). In a 100-mL beaker, which was used as the 
developing chamber, the solvent was filled 0.5 cm from the bottom, or 8.3 mL. A strip of 
filter paper was placed in the beaker, and the plate was placed in the beaker and covered 
with a watch glass to develop. Each plate took approximately 1 hour and 20 minutes to 
run to completion. See Table A4 for calculated retention factor values. 
 
Cells 
 Spleen cells obtained from either the C57 mouse strain or Balb/c mouse strain 
were used for the assessment of the proliferative effects of the elderberry extract samples 
on spleen cells. Initial experiments were conducted with C57 mice, but due to the low 
counts obtained, the spleen cells were replaced with those of Balb/c mice. A human skin 
melanoma cell line (Mewo) was obtained from Dr. Visalli’s laboratory and was used to 
assess the suppressive capabilities of the elderberry extracts on tumor cell propagation. 
The Mewo cells were maintained in Eagle MEM X media supplemented with 10% fetal 
bovine serum (FBS), and sub-cultured every 4-5 days. 
 
Spleen Cell Preparation 
 Each mouse was sacrificed through cervical dislocation. The spleen was removed 
from the mouse by first thoroughly wetting the right side of the mouse with ethanol to 
eliminate interference. Using a pair of heat-sterilized scissors, a left paramedial dorsal 
incision was made to expose the abdominal wall. Another incision was made on the 
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abdominal wall to provide access to the spleen. The spleen was lifted out of the cavity 
using heat-sterilized forceps, and any fatty tissue was cut away. The spleen was placed in 
a sterile petri dish, containing 1 mL of RPMI-1640 nutrient media supplemented with 
10% FBS, on top of a heat-sterilized mesh screen. Using the plunger of a syringe, the 
spleen was pushed through the mesh screen in order to create a single cell suspension. 
Using a syringe and a 25 gauge needle, the cell suspension was collected and placed in a 
sterile vial. In a separate tube, 295 µL of isotonic buffer, 100 µL of 0.4% Trypan Blue in 
PBS, 100 µL of Lyse buffer, and 5 µL of the spleen cells were added. 10 µL of this 
mixture was pipetted onto a hemocytometer and the cells were counted. The 1 mL of 
cells was diluted with enough media to create a 1 x 10
6
 cells/well concentration. 
 
Spleen Cell Proliferation Assay with Resolved Components 
 To assess the mitogenic effects of the elderberry extract fractions collected from 
the column, a spleen-cell proliferation assay was conducted. For this assay, two C57 mice 
were sacrificed; one young (4 months) and one old (1 ½ year old). 100 µL of RPMI-1640 
nutrient media containing 10% FBS were added to each experimental well of a 96-well 
cell culture plate, followed by 100 µL of spleen cells were added to the wells. 10 µL of 
each sample resolved from the column were applied to the cells, after which the cells 
were incubated in 5% CO2 and 37
o
C. After 48 hours, the plates were removed from the 
incubator, and 1 mCi/mL of tritiated thymidine was added to each experimental well. The 
plates were placed back into the incubator for an additional 24 hours, and then harvested. 
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Spleen Cell Proliferation Assay with 1:2 Methanol Dilution 
 Previously conducted experiments indicate the ability of methanol to function as a 
mitogen for murine spleen cells (Zandonai 2010). To eliminate the speculation of any 
interference of methanol on spleen cell propagation in these trials, a proliferation assay 
was performed with methanol. Due to the extremely low counts of the previous assays, 
the C57 mice were not used. Instead, a young Balb/c mouse (4 months old) was 
sacrificed for this experiment. The 100 µL of RPMI-1640 media containing 10% FBS 
and 100 µL of cells were added to each experimental well of a 96-well cell culture plate. 
A 1:2 serial dilution was conducted for methanol with deionized water, and 10 μL of each 
methanol dilution was applied to the spleen cells, followed by 25μg/mL of concanavalin 
A. The cells were incubated in 5% CO2 and 37
o
C. After 48 hours, the plates were 
removed from the incubator, and 1 mCi/mL of tritiated thymidine was added to each 
experimental well. The plates were placed back into the incubator for an additional 24 
hours, and then harvested. 
 
Spleen Cell Proliferation Assay with Column Eluent 
 A spleen cell proliferation assay with Balb/c spleen cells was conducted using the 
eleven solutions prepared as the mobile phase (Appendix C) during the column 
chromatography without running them through the column.16.5 mL of each individual 
solution was evaporated down to 2 mL samples using the rotary evaporator as had been 
done to the fractions resolved from the column. 100 µL of RPMI-1640 containing 10% 
FBS and 100 µL of cells were added to each experimental well of a 96-well cell culture 
plate. 10 µL of the 2-mL mobile phase samples were incubated with the cells and 25 
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µg/mL of concanavalin A. The cells were incubated in 37
o
C and 5% CO2. After 48 hours, 
the cells were tagged with 1 mCi/mL of tritiated thymidine. The plates were placed back 
into the incubator for an additional 24 hours, and then harvested. 
 
Pooling and Drying Samples 
 According to Figure B9 produced from the results derived from the first assay, the 
94 samples were pooled according to their levels of activity (Table A8).  
 Due to the relatively high counts produced during the spleen-cell assays 
conducted with methanol, two alternatives routes were proposed to rid the samples of 
their methanol content. One route was to dialyze the samples with sterile phosphate 
buffered saline (PBS). 500 µL of pooled sample numbers 14, 16, 22, 24, 25, 29, and 32 
were dialyzed. 0.5-3-mL capacity Slide-A-Lyzer dialysis cassettes were obtained and 
prepared by removing them from their protective pouches and immersing them in PBS 
(the chosen dialysis buffer) for 2 minutes. Next each sample was added to a separate 
cassette by filling a syringe with the sample and inserting the tip of the needle through 
one of the syringe ports on the corner of the cassette. The sample was injected slowly and 
the air was removed by pulling up the syringe piston before removing the needle. The 
dialysis cassettes were attached to buoys to allow for floatation and placed in beakers 
contained 250 mL of PBS. The PBS was replaced with a fresh amount every 2 hours for 4 
hours, and finally the samples were left overnight in the dialysis buffer. The dialyzed 
samples were removed from the cassettes by inserting the tip of the needle of a syringe 
into a portal other than that of the one used to insert the sample. The samples were stored 
in sterile micro-centrifuge tubes. Another drying technique involved the complete 
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evaporation off the solvent from each sample using the rotary evaporator, followed by 
dissolving the dry sample in PBS. Another 500 µL portion of the same pooled samples 
was evaporated using the rotary evaporator until just a film coated the round bottom flask 
(Figure B2a). Then, 500 µL of PBS was added to the round bottom flask and the film of 
sample was dissolved into the PBS and stored in sterile tubes. 
 To eliminate any doubt of the presence of methanol in the samples, a final drying 
technique was instated. A centrifuge connected to a vacuum pump (Figure B2b) was used 
to dry the pooled samples completely. 0.5 mL of sample each sample was placed in an 
autoclaved microcentrifuge tube, and the opening of the tubes was covered with parafilm. 
Using a 22 gauge needle, a series of holes were poked into the parafilm, which would 
ensure the removal of the liquid from the tube and maintenance of the desired compounds 
in the tube. The samples were placed into the centrifuge chamber and the centrifuge was 
allowed to run on medium heat (36
o
C), until the samples were dry. The samples were 
dissolved in sterile PBS by adding 0.5 mL of PBS to the microcentrifuge tube and 
vortexing until homogenous. 
 
Spleen Cell Proliferation Assay with Dialyzed and Evaporated Samples 
 A spleen cell proliferation assay of the dialyzed and evaporated samples was 
conducted using the spleen of a young Balb/c mouse. 100 µL of RPMI-1640 containing 
10% FBS and 100 µL of cells were added to each experimental well. 10 µL and 20 µL of 
each samples were incubated with the cells and 25 µg/µL of concanavalin A. The cells 
were incubated in 37
o
C and 5% CO2. After 48 hours, the cells were tagged with 1 
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mCi/mL tritiated thymidine. The plates were placed back into the incubator for an 
additional 24 hours, and then harvested. 
 
Spleen Cell Proliferation Assay with Dried Samples 
 A spleen cell proliferation assay was initiated using the spleen of a young Balb/c 
mouse. A 96-well cell culture plate was obtained and 100 µL of RPMI-1640 containing 
10% FBS and 100 µL of cells were added to each experimental well. 10 µL and 20 µL of 
each sample were incubated with the cells and 2.5 µL of concanavalin A. The cells were 
incubated in 37
o
C and 5% CO2. After 48 hours, the cells were tagged with 1 mCi/mL of 
tritiated thymidine. The plates were placed back into the incubator for an additional 24 
hours, and then harvested. This assay was repeated to confirm the results obtained. 
 
Cell Harvesting 
 The cells were washed with PBS. The DNA of the cells was precipitated onto 
filter paper using 10%TCA and the discs were placed in vials and into a scintillation 
counter to assess the counts per minute of cellular division (Figure B3a,b). 
 
Tumor Cell Proliferation Assay with Dried Samples 
 To assess the inhibitory effects of the elderberry extract samples on tumor cell 
proliferation, an assay was set up to incubate the cells with each pooled sample. 100 µL 
of Eagle MEM X media supplemented with 10% FBS was added to each experimental 
well of a 96-well cell culture plate, followed by 5 µL of cells (50,000 cells). The cells 
were seeded 24 hours before adding sample. 10 µL and 20 µL of each sample were each 
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added to an experimental well. The cells were incubated in 5% CO2 and 37
o
C for 48 
hours. The cells were tagged with 1 mCi/mL of tritiated thymidine. The plates were 
placed back into the incubator for an additional 24 hours, and then harvested. This assay 
was repeated to validate the results achieved. 
 
Apoptosis 
 To attribute the tumor cell death to the samples resolved from the elderberry 
extract, the apoptotic activity of the cells following exposure to the samples was 
evaluated. The colorimetric assay used assessed caspase 8 activity through the hydrolysis 
of the peptide Acetyl-Ile-Glu-Thr-Asp p-nitroaniline, which results in the release of a p-
Nitroaniline (pNA) moiety.  
In order to do this, a 96-well was obtained and 5 μL of Mewo cells (50,000 cells) 
were seeded into each well, followed by 100 μL of Eagle MEM X, containing 10% FBS 
and left overnight. 10 μL of each active berry (Figure B15) was added to a well of cells 
and allowed to incubate for either an additional 24 or 48 hours. The cells were lysed to 
reveal their contents. 
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RESULTS 
 
Resolution of Elderberry Extract 
 The resolution of the standardized elderberry extract resulted in the acquisition of 
94 separate 16.5-mL increment samples. The polarity of the mobile phase altered the 
colors of the fractions that were pulled through the column; as the polarity decreased, 
darker pigmented liquid eluted through the column. The colors of the samples collected 
varied from a pale orange color to a deep purple color. The time at which it took to 
collect each fraction also varied according to the polarity of the eluent added to the 
column. The initial collection time of the fractions containing 100% water and 50 mL 
0.01N HCl was 0.4 mL/min while the final collection time of the fractions containing 
100% methanol and 50 mL 0.01N HCl was 0.15 mL/min. For complete collection times, 
see Table A2. 
 
Preliminary Identification through Thin Layer Chromatography 
 Thin layer chromatography resulted in obtaining several Rf values for the 94 
samples from the column. Without a standard, one cannot compare the Rf values and 
therefore cannot identify the composition of the samples.
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Spleen Cell Proliferation Assay with Resolved Components 
 The spleen cell proliferation assay resulted in the varying induction of spleen cell 
proliferation from the different resolved components of the column (Figure B9). The 
samples were pooled based on similar proliferative characteristics. Based on the 
published data reflecting the immune-enhancing capability of elderberry as a whole, it 
was hypothesized that the elderberry fractions would induce a significantly positive effect 
upon spleen cell proliferation. The counts were still relatively low as compared to the 
previous counts obtained from spleen cell incubation with concanavalin A, the positive 
control for these proliferative assays. Concanavalin A induces spleen cell proliferation, 
obtaining counts over 10,000 cpm. The highest count obtained from incubation of the 
spleen cells with the fractions resolved from the column was 76% less than that of con A. 
Although the counts obtained were relatively low, peaks of activity were noted, 
indicating a varying range of composition between the fractions obtained from the 
column. 
 
Spleen Cell Proliferation Assay with 1:2 Methanol Dilution 
 As shown in previous experiments, methanol proved to induce significant 
proliferation in murine spleen cells (Figure B10) and therefore had to be completely 
eliminated from the samples in order to obtain a more accurate assessment of the berry 
extract samples’ induction of spleen cell propagation. As compared to the cells incubated 
with con A alone (shown in light pink), the 1:2, 1:16, and 1:32 dilutions of methanol 
induced significantly higher counts. Due to the fact that even trace amounts of methanol 
(1:32 dilution) resulted in 4% higher counts than those of the cells incubated with con A, 
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proved that methanol must be eliminated from the samples in order to obtain an accurate 
assessment of the elderberry extract samples’ ability to induce spleen cell proliferation. 
 
Spleen Cell Proliferation Assay with Column Eluent 
 The mobile phase used in running the column contained varying amounts of 
methanol and therefore could be the sole inducer of spleen cell proliferation in the 
previous experiments. Each of the solutions of the mobile phase (10% MeOH thru 80% 
MeOH) produced significantly high counts comparable to those of the spleen cells 
incubated with just con A. The samples containing 90% and 100% MeOH, did not induce 
significant proliferation in the spleen cells. The results from this assay confirm the 
presence of methanol in the evaporated samples and their stimulatory effects on spleen 
cell propagation (Figure B11). These results confirmed that another drying technique 
must be performed to rid the solvent from the berry extract samples. 
 
Spleen Cell Proliferation Assay with Dialyzed and Evaporated Samples 
 This assay was performed on the samples that had been either dialyzed with PBS 
or evaporated off using a rotary evaporator. As compared to the control (shown in light 
pink), dialyzed samples 14, 16, 24, and 25 all induced higher proliferative counts (Figure 
B12). The rest of the dialyzed samples and all of the evaporated samples did not induce 
signification spleen cell proliferation.  
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Pooling and Drying Samples 
 The initial rotary evaporation of the solvents resulted in the removal of the bulk of 
the solvents in the elderberry fractions resolved from the column. Further evaporation 
using the rotary evaporator and dialysis also failed in the complete removal of the 
methanol from the samples. The final method of centrifugation using a vacuum pump 
was successful in eliminating any traces of methanol that would affect the results of the 
experiments. Through GCMS analysis, the samples were tested for the absence of 
methanol and proved successfully free of the solvent. 
 
Spleen Cell Proliferation Assay with Dried Samples 
 Of the 41 total elderberry extract samples resolved from the column, several of 
the elderberry samples induced a greater amount of spleen cell proliferation as compared 
to samples just incubated with con A. Samples numbers 5, 6, 12, 13, 14, 15, 16, 17, 19, 
20, 22, 24, 25, 29, and 32 all induced proliferation to a greater extent than the positive 
control, with at least a 4% greater proliferation than the positive control when 10 μL of 
each sample was added. Samples 14, 16, 17, 22, 24, and 32 all exhibited increased 
proliferative effects when 20 μL of sample were added, but to a lesser degree. When 20 
μL of sample was added, samples 5, 6, 12, 13, 15, 19, 20, 25, and 29 had reduced 
proliferation; less than that of the positive control. The increased sample amount induced 
proliferation in sample #28, which did not induce a greater proliferation when 10 μL of 
sample was added. This assay was repeated to confirm the results and a similar pattern of 
results was obtained (Figures B13, B14).  
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Tumor Cell Proliferation Assay with Dried Samples 
 This proliferative assay revealed significant suppressive effects of the elderberry 
extract samples. This assay was repeated and similar results were obtained each time 
(Figures B15, B16). When 10 μL of sample were added, samples numbers 1, 2, 3, 4, 6, 7, 
8, 9, 10, 11, 13, 15, 19, 21, 23, 26, 27, 28, 30, 31, 39, 40, 41 achieved successful 
suppression over 60%. All but samples 14, 22, and 32 suppressed tumor proliferation by 
at least 60%. 
 
Apoptosis 
 After 24 hours, significantly increased apoptotic activity was noted in tumor cells 
incubated with 10 µL of samples 1, 11, 26, 31, 36, and 39 (Table A16). Tumor cells 
incubated with sample for 48 hours, showed a couple of different activities. In the well 
containing sample #2, the apoptotic increased between the 24-hour interval and the 48-
hour assessment. However, in the wells containing samples 11, 26, 27, 31, and 36, 
apoptotic activity actually decreased. This could be attributed to the fact that certain 
peptides are degraded in a timely manner and would therefore not show up after 48 hours. 
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DISCUSSION 
 
 Although thorough investigation of the therapeutic effects of elderberry must still 
be conducted, preliminary research suggests that elderberry fruit may be useful in treating 
various ailments. Initial trials were conducted applying the elderberry extract fractions 
with spleen cells from both C57 and Balb/c mice, and they resulted in very low counts of 
both the experimental groups and the controls. This possibly corresponded with the fact 
that the accuracy of tritiated thymidine diminshes with age. This was rectified through the 
purchase of a new batch of tritiated thymidine, and the rest of the trials were conducted 
with cells obtained from only Balb/c mice. The results from the spleen cell proliferation 
assay indicated a direct effect of the components of elderberry on the proliferative 
behavior of the immune cells vital in the recognition and targeting of tumor cells. As a 
whole, elderberry possesses several beneficial qualities including antiangiogenic,anti-
carcinogenic, and immune-enhancing capabilities. All of which are essential in the 
combat against tumor cell propagation. Therefore, it was hypothesized that elderberry 
extract fractions would induce significant proliferative effects on murine spleen cells. 
However, the counts obtained were greater than expected and provide an optimistic 
outlook on the potential of the individual components of elderberry. The overall decrease 
in efficiency of most of the samples in their mitogenic effects on T cell lymphocytes, 
seen when 20 μL of each sample were added to the spleen cells, indicated the need to 
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determine an optimal concentration of the therapeutic agents. An excess amount of 
sample proved to reduce the beneficial properties of the extracts.  
 The tumor cell proliferation assays served to assess the inhibitory effects of the 
resolved fractions of elderberry, and resulted in surprisingly high levels of suppression. 
Not only did most of the samples repress the proliferative behavior of the tumor cells, the 
level of suppression achieved was exceedingly high. 
 The assessments of immune cell proliferation and tumor cell suppression were in 
vitro studies, designed to evaluate the direct effects of the different components of 
elderberry. The results validate the role of elderberry as a possible therapeutic agent in 
both augmenting the immune system’s response to tumor cells, as well as an agent that 
will directly target and eliminate tumor cells. 
 The results from the assessment of apoptotic activity reveal an additional activity 
of the elderberry extract fractions. The samples evaluated, not only inhibit tumor cell 
proliferation as displayed in the previous proliferation assays, but they actually induce 
apoptosis in the tumor cells as displayed in this colorimetric assay. 
Upon the successful completion of these in vitro studies, the separation techniques 
of elderberry may be applied to in vivo studies that may validate the use of the identified 
components in the elderberry extract as viable therapeutic agents both in immunotherapy 
as well as natural chemotherapy.  
 
Proposed Method of Identification 
As a means of identification of the actual stimulatory components and inhibitory 
components of the berry extract, there are several proposed techniques that can be 
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utilized. The composition of the samples will be tested through two-dimensional nuclear 
magnetic resonance techniques including Correlation Spectroscopy (COSY) and 
Distortionless Enhancement by Polarization Transfer (DEPT) to elucidate the structures 
of the compounds contained within the active samples. COSY will contribute to the 
identification of nuclei that are coupled to each other, and it is useful for interpreting the 
complicated spectra which will be produced. Diffusion Ordered Spectroscopy (DOSY) 
NMR will be utilized due to its ability to differentiate NMR signals based on the 
diffusion rates of component compounds in a solvent. Diffusion coefficient differences 
will be enhanced by polyvinylpyrrolidone. 
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Appendix A:  Tables 
 
 
 
Table A1.  The individual components found in elderberry and their proposed benefits. 
 
Category Compounds General known Therapeutic Effects 
Phenolic acids 
Malic acid 
Benzoic acid 
Cinnamic acid 
Cholorogenic acid 
Caffic acid 
Palmitic acid 
Apoptotic effects on tumor cells 
Inhibitory effects on tumor cell 
proliferation 
 
Flavonoids 
Rutin 
Fight arterial and immune system 
aging 
Antioxidants 
 
Isoquercitrin 
Quercitrin 
Hyperoside 
Astagalin 
Nicotoflorin 
Tannins Tannins 
Immune stimulant 
Tumor suppressors 
Epicatechin Epicatechin Reduced risk of cancer 
Catechin Catechin Tumor suppressor 
Anthocyanins 
Cyanidin-3-glucoside 
Inhibitory effects on tumor cell 
proliferation 
Inhibitors of angiogenesis 
Initiators of apoptosis 
Cyanidin-3,5-diglucoside 
Cyanidin-3 sambubioside-
5-glycoside 
Cyanidin-3-
rhamnoglucoside 
Cyanidin-3-xyloglucoside 
Proanthocyanidins Proanthocyanidins Antioxidant 
Vitamin A Vitamin A 
Immune enhancement 
Antioxidant 
Vitamin C Vitamin C 
Immune enhancement 
Antioxidant 
Anti-histamine 
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Table A2.  The collection times of the berry extract fractions resolved through column 
chromatography. 
 
Fraction Numbers mL/min 
1-2 0.4 
3-10 0.5 
11-19 0.4 
20-25 0.3 
26-85 0.2 
86-94 0.15 
 
 
 
Table A3.  The evaporation times of the berry extract fractions using a rotary evaporator. 
 
Fraction Numbers Methanol Content Time (minutes) 
1-6 0% 17.5 
7-15 0-10% 16.25 
16-22 10-20% 16 
23-46 20-50% 14.5 
47-53 50-60% 14.25 
54-66 60-70% 13 
67-78 70-80% 11.5 
79-86 80-90% 10 
87-93 90-100% 8.75 
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Table A4.  Rf values for berry extract fractions calculated using the following equation:   
Rf = (distance traveled by sample) ÷ (distance traveled by solvent). 
 
Sample 
Number 
Distance Traveled 
By Sample 
Distance Traveled 
By Solvent 
Calculated Rf 
Value 
8 4.70 cm 6.49 cm 0.724 
9 4.55 cm 6.45 cm 0.705 
10 5.05 cm 6.50 cm 0.777 
11 4.70 cm 6.55 cm 0.718 
14 3.65 cm 6.45 cm 0.566 
17 3.40 cm 6.50 cm 0.523 
18 4.35 cm 6.46 cm 0.673 
19 4.65 cm 6.45 cm 0.721 
20 3.65 cm 6.50 cm 0.562 
21 3.70 cm 6.40 cm 0.578 
22 3.90 cm 6.45 cm 0.605 
24 3.10 cm 6.42 cm 0.483 
26 4.10 cm 6.45 cm 0.636 
27 3.79 cm 6.50 cm 0.583 
29 4.08 cm 6.45 cm 0.633 
31 4.40 cm 6.43 cm 0.684 
32 3.75 cm 6.65 cm 0.564 
34 4.25 cm 6.50 cm 0.654 
35 4.50 cm 6.50 cm 0.692 
38 4.50 cm 6.52 cm 0.690 
39 4.45 cm 6.50 cm 0.685 
40 4.12 cm 6.52 cm 0.632 
41 3.90 cm 6.50 cm 0.600 
42 4.59 cm 6.53 cm 0.703 
44 4.80 cm 6.49 cm 0.740 
45 5.35 cm 6.51 cm 0.822 
47 4.75 cm 6.48 cm 0.733 
48 5.85 cm 6.45 cm 0.907 
50 4.30 cm 6.40 cm 0.672 
51 4.91 cm 6.45 cm 0.761 
52 5.10 cm 6.52 cm 0.782 
53 5.25 cm 6.45 cm 0.814 
54 5.72 cm 6.50 cm 0.880 
55 5.62 cm 6.50 cm 0.865 
57 4.68 cm 6.42 cm 0.729 
60 4.75 cm 6.45 cm 0.736 
61 4.70 cm 6.48 cm 0.725 
62 4.82 cm 6.45 cm 0.747 
63 4.80 cm 6.45 cm 0.744 
64 5.00 cm 6.45 cm 0.775 
65 4.75 cm 6.50 cm 0.731 
66 4.95 cm 6.49 cm 0.763 
68 4.15 cm 6.50 cm 0.638 
71 4.86 cm 6.53 cm 0.744 
73 5.03 cm 6.55 cm 0.768 
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Table A4,  continued. 
74 4.99 cm & 5.81 cm 6.58 cm 0.758 & 0.883 
75 5.18 cm & 6.00 cm 6.47 cm 0.801 & 0.927 
76 4.91 cm 6.45 cm 0.761 
77 4.78 cm 6.51 cm 0.734 
78 4.20 cm & 5.48 cm 6.45 cm 0.651 & 0.850 
79 4.58 cm & 5.47 cm 6.45 cm 0.837 & 0.848 
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Table A5.  Results for spleen cell proliferation assay with resolved berry components. 
 
Well Contents CPM Well Contents CPM 
Young Resting 73.00 Old + 10 µL Sample #30 6,975.00 
Young Resting 81.00 Old + 10 µL Sample #31 4,503.00 
Young Resting 83.00 Old + 10 µL Sample #32 3,630.00 
Young + 2.5 µL 1:10 conA 516.00 Old + 10 µL Sample #33 4,297.00 
Young + 2.5 µL 1:10 conA 603.00 Old + 10 µL Sample #34 7,625.00 
Young + 2.5 µL 1:10 conA 524.00 Old + 10 µL Sample #35 4,298.00 
Young + 2.5 µL 1:20 conA 726.00 Old + 10 µL Sample #36 4,698.00 
Young + 2.5 µL 1:20 conA 689.00 Old + 10 µL Sample #37 419.00 
Young + 2.5 µL 1:20 conA 635.00 Old + 10 µL Sample #38 421.00 
Young + 2.5 µL crude berry 104.00 Old + 10 µL Sample #39 2,071.00 
Young + 2.5 µL crude berry 94.00 Old + 10 µL Sample #40 2,713.00 
Young + 2.5 µL crude berry 98.00 Old + 10 µL Sample #41 2,383.00 
Young + 5 µL crude berry 77.00 Old + 10 µL Sample #42 2,479.00 
Young + 5 µL crude berry 95.00 Old + 10 µL Sample #43 2,794.00 
Young + 5 µL crude berry 95.00 Old + 10 µL Sample #44 4,354.00 
Young + 10 µL crude berry 175.00 Old + 10 µL Sample #45 2,523.00 
Young + 10 µL crude berry 148.00 Old + 10 µL Sample #46 1,867.00 
Young + 10 µL crude berry 142.00 Old + 10 µL Sample #47 429.00 
Old Resting 327.00 Old + 10 µL Sample #48 2,270.00 
Old Resting 423.00 Old + 10 µL Sample #49 1,025.00 
Old Resting 450.00 Old + 10 µL Sample #50 1,010.00 
Old + 2.5 µL 1:10 conA 404.00 Old + 10 µL Sample #51 834.00 
Old + 2.5 µL 1:10 conA 419.00 Old + 10 µL Sample #52 3,335.00 
Old + 2.5 µL 1:10 conA 338.00 Old + 10 µL Sample #53 4,379.00 
Old + 2.5 µL 1:20 conA 98.00 Old + 10 µL Sample #54 3,850.00 
Old + 2.5 µL 1:20 conA 99.00 Old + 10 µL Sample #55 4,291.00 
Old + 2.5 µL 1:20 conA 118.00 Old + 10 µL Sample #56 3,844.00 
Old + 2.5 µL crude berry 72.00 Old + 10 µL Sample #57 1,323.00 
Old + 2.5 µL crude berry 92.00 Old + 10 µL Sample #58 3,498.00 
Old + 2.5 µL crude berry 76.00 Old + 10 µL Sample #59 1,933.00 
Old + 5 µL crude berry 121.00 Old + 10 µL Sample #60 364.00 
Old + 5 µL crude berry 152.00 Old + 10 µL Sample #61 1,048.00 
Old + 5 µL crude berry 202.00 Old + 10 µL Sample #62 2,037.00 
Old + 10 µL crude berry 731.00 Old + 10 µL Sample #63 1,007.00 
Old + 10 µL crude berry 780.00 Old + 10 µL Sample #64 2,039.00 
Old + 10 µL crude berry 623.00 Old + 10 µL Sample #65 4,397.00 
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Table A5,  continued.  
Old + 10 µL Sample #1 180.00 Old + 10 µL Sample #66 4,066.00 
Old + 10 µL Sample #2 62.00 Old + 10 µL Sample #67 3,721.00 
Old + 10 µL Sample #3 78.00 Old + 10 µL Sample #68 3,680.00 
Old + 10 µL Sample #4 50.00 Old + 10 µL Sample #69 1,386.00 
Old + 10 µL Sample #5 103.00 Old + 10 µL Sample #70 2,335.00 
Old + 10 µL Sample #6 318.00 Old + 10 µL Sample #71 3,906.00 
Old + 10 µL Sample #7 1,794.00 Old + 10 µL Sample #72 3,508.00 
Old + 10 µL Sample #8 207.00 Old + 10 µL Sample #73 2,628.00 
Old + 10 µL Sample #9 315.00 Old + 10 µL Sample #74 1,822.00 
Old + 10 µL Sample #10 392.00 Old + 10 µL Sample #75 2,466.00 
Old + 10 µL Sample #11 316.00 Old + 10 µL Sample #76 3,092.00 
Old + 10 µL Sample #12 550.00 Old + 10 µL Sample #77 5.00 
Old + 10 µL Sample #13 929.00 Old + 10 µL Sample #78 4.00 
Old + 10 µL Sample #14 214.00 Old + 10 µL Sample #79 13.00 
Old + 10 µL Sample #15 319.00 Old + 10 µL Sample #80 3.00 
Old + 10 µL Sample #16 1,845.00 Old + 10 µL Sample #81 369.00 
Old + 10 µL Sample #17 929.00 Old + 10 µL Sample #82 1,659.00 
Old + 10 µL Sample #18 1,368.00 Old + 10 µL Sample #83 1,850.00 
Old + 10 µL Sample #19 380.00 Old + 10 µL Sample #84 2,971.00 
Old + 10 µL Sample #20 1,259.00 Old + 10 µL Sample #85 611.00 
Old + 10 µL Sample #21 2,069.00 Old + 10 µL Sample #86 1,039.00 
Old + 10 µL Sample #22 724.00 Old + 10 µL Sample #87 1,328.00 
Old + 10 µL Sample #23 2,896.00 Old + 10 µL Sample #88 1,844.00 
Old + 10 µL Sample #24 6,012.00 Old + 10 µL Sample #89 230.00 
Old + 10 µL Sample #25 3,888.00 Old + 10 µL Sample #90 961.00 
Old + 10 µL Sample #26 4,136.00 Old + 10 µL Sample #91 671.00 
Old + 10 µL Sample #27 4,147.00 Old + 10 µL Sample #92 168.00 
Old + 10 µL Sample #28 3,961.00 Old + 10 µL Sample #93 285.00 
Old + 10 µL Sample #29 3,041.00 Old + 10 µL Sample #94 207.00 
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Table A6.  Results for spleen cell proliferation assay with 1:2 dilution of methanol. 
 
Well Contents CPM Well Contents CPM 
Resting 217.00 MeOH 1:16 236.00 
Resting 189.00 MeOH 1:16 170.00 
Resting 326.00 MeOH 1:16 166.00 
2.5 µL 1:10 conA 14,042.00 MeOH 1:32 151.00 
2.5 µL 1:10 conA 11,816.00 MeOH 1:32 269.00 
2.5 µL 1:10 conA 10,865.00 MeOH 1:32 237.00 
5 µL 1:10 conA 6,029.00 MeOH + conA 10,077.00 
5 µL 1:10 conA 6,079.00 MeOH + conA 13,314.00 
5 µL 1:10 conA 8,922.00 MeOH + conA 27,005.00 
10 µL 1:10 conA 4,413.00 MeOH 1:2 + conA 29,545.00 
10 µL 1:10 conA 4,115.00 MeOH 1:2 + conA 22,392.00 
10 µL 1:10 conA 166.00 MeOH 1:2 + conA 20,792.00 
MeOH 103.00 MeOH 1:4 + conA 13,949.00 
MeOH 158.00 MeOH 1:4 + conA 12,542.00 
MeOH 120.00 MeOH 1:4 + conA 13,668.00 
MeOH 1:2 169.00 MeOH 1:8 + conA 14,928.00 
MeOH 1:2 137.00 MeOH 1:8 + conA 15,867.00 
MeOH 1:2 164.00 MeOH 1:8 + conA 19,069.00 
MeOH 1:4 121.00 MeOH 1:16 + conA 29,783.00 
MeOH 1:4 128.00 MeOH 1:16 + conA 30,328.00 
MeOH 1:4 188.00 MeOH 1:16 + conA 26,508.00 
MeOH 1:8 318.00 MeOH 1:32 + conA 19,524.00 
MeOH 1:8 129.00 MeOH 1:32 + conA 16,779.00 
MeOH 1:8 391.00 MeOH 1:32 + conA 16,530.00 
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Table A7.  Results for spleen cell proliferation assay with mobile phase. 
 
Well Contents CPM Well Contents CPM 
Resting 187.00 50% MeOH + conA 47.00 
Resting 272.00 50% MeOH + conA 7,477.00 
Resting 381.00 50% MeOH + conA 6,892.00 
2.5 µL 1:10 conA 5,555.00 60% MeOH 237.00 
2.5 µL 1:10 conA 14,912.00 60% MeOH 187.00 
2.5 µL 1:10 conA 17,658.00 60% MeOH 19.00 
10% MeOH 215.00 60% MeOH + conA 6,838.00 
10% MeOH 160.00 60% MeOH + conA 5,502.00 
10% MeOH 86.00 60% MeOH + conA 8,253.00 
10% MeOH + conA 9,341.00 70% MeOH 108.00 
10% MeOH + conA 6,383.00 70% MeOH 110.00 
10% MeOH + conA 7,313.00 70% MeOH 139.00 
20% MeOH 24.00 70% MeOH + conA 8,629.00 
20% MeOH 98.00 70% MeOH + conA 17.00 
20% MeOH 491.00 70% MeOH + conA 6,250.00 
20% MeOH + conA 14,030.00 80% MeOH 158.00 
20% MeOH + conA 13,016.00 80% MeOH 171.00 
20% MeOH + conA 12,082.00 80% MeOH 363.00 
30% MeOH 17.00 80% MeOH + conA 2,515.00 
30% MeOH 75.00 80% MeOH + conA 4,966.00 
30% MeOH 218.00 80% MeOH + conA 4,563.00 
30% MeOH + conA 11,403.00 90% MeOH 391.00 
30% MeOH + conA 12,213.00 90% MeOH 117.00 
30% MeOH + conA 8,394.00 90% MeOH 87.00 
40% MeOH 22.00 90% MeOH + conA 142.00 
40% MeOH 254.00 90% MeOH + conA 87.00 
40% MeOH 111.00 90% MeOH + conA 186.00 
40% MeOH + conA 11,241.00 100% MeOH 135.00 
40% MeOH + conA 7,037.00 100% MeOH 108.00 
40% MeOH + conA 2,071.00 100% MeOH 522.00 
50% MeOH 138.00 100% MeOH + conA 303.00 
50% MeOH 122.00 100% MeOH + conA 551.00 
50% MeOH 119.00 100% MeOH + conA 711.00 
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Table A8.  Pooled samples based on the results in Figure B9. 
 
Sample Number Pooled Sample # 
49 
23 
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41 
 
Table A9.  Results for spleen cell proliferation assay with select dialyzed or evaporated 
samples. 
 
Well Contents CPM Well Contents CPM 
Resting 242.00 Evap PS #25 554.00 
Resting 274.00 Evap PS #29 589.00 
Resting 472.00 Evap PS #32 505.00 
2.5 µL 1:10 conA 2,915.00 Dialyzed PS #14 + conA 4,538.00 
2.5 µL 1:10 conA 2,798.00 Dialyzed PS #16 + conA 4,541.00 
2.5 µL 1:10 conA 2,779.00 Dialyzed PS #22 + conA 2,122.00 
Dialyzed PS #14 511.00 Dialyzed PS #24 + conA 3,202.00 
Dialyzed PS #16 526.00 Dialyzed PS #25 + conA 2,989.00 
Dialyzed PS #22 575.00 Dialyzed PS #29 + conA 2,567.00 
Dialyzed PS #24 595.00 Dialyzed PS #32 + conA 2,824.00 
Dialyzed PS #25 492.00 Evap PS #14 + conA 2,501.00 
Dialyzed PS #29 483.00 Evap PS #16 + conA 2,614.00 
Dialyzed PS #32 538.00 Evap PS #22 + conA 2,822.00 
Evap PS #14 515.00 Evap PS #24 + conA 2,852.00 
Evap PS #16 513.00 Evap PS #25 + conA 2,667.00 
Evap PS #22 490.00 Evap PS #29 + conA 543.00 
Evap PS #24 469.00 Evap PS #32 + conA 1,885.00 
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Table A10.  Results for spleen cell proliferation assay with pooled samples. 
 
Well Contents CPM  Well Contents CPM 
Resting 191.00  Pooled Sample #39 489.00 
Resting 212.00  Pooled Sample #40 438.00 
Resting 249.00  Pooled Sample #41 450.00 
2.5 µL 1:10 conA 200.00  PS #1 + conA 1,594.00 
2.5 µL 1:10 conA 232.00  PS #2 + conA 146.00 
2.5 µL 1:10 conA 238.00  PS #3 + conA 265.00 
Pooled Sample #1 143.00  PS #4 + conA 500.00 
Pooled Sample #2 157.00  PS #5 + conA 476.00 
Pooled Sample #3 278.00  PS #6 + conA 488.00 
Pooled Sample #4 447.00  PS #7 + conA 397.00 
Pooled Sample #5 523.00  PS #8 + conA 418.00 
Pooled Sample #6 472.00  PS #9 + conA 348.00 
Pooled Sample #7 551.00  PS #10 + conA 381.00 
Pooled Sample #8 443.00  PS #11 + conA 458.00 
Pooled Sample #9 439.00  PS #12 + conA 506.00 
Pooled Sample #10 427.00  PS #13 + conA 547.00 
Pooled Sample #11 367.00  PS #14 + conA 386.00 
Pooled Sample #12 513.00  PS #15 + conA 465.00 
Pooled Sample #13 432.00  PS #16 + conA 417.00 
Pooled Sample #14 365.00  PS #17 + conA 481.00 
Pooled Sample #15 471.00  PS #18 + conA 449.00 
Pooled Sample #16 395.00  PS #19 + conA 440.00 
Pooled Sample #17 491.00  PS #20 + conA 428.00 
Pooled Sample #18 421.00  PS #21 + conA 411.00 
Pooled Sample #19 482.00  PS #22 + conA 397.00 
Pooled Sample #20 500.00  PS #23 + conA 396.00 
Pooled Sample #21 466.00  PS #24 + conA 390.00 
Pooled Sample #22 436.00  PS #25 + conA 487.00 
Pooled Sample #23 496.00  PS #26 + conA 403.00 
Pooled Sample #24 423.00  PS #27 + conA 393.00 
Pooled Sample #25 433.00  PS #28 + conA 576.00 
Pooled Sample #26 434.00  PS #29 + conA 307.00 
Pooled Sample #27 459.00  PS #30 + conA 452.00 
Pooled Sample #28 491.00  PS #31 + conA 422.00 
Pooled Sample #29 380.00  PS #32 + conA 247.00 
Pooled Sample #30 567.00  PS #33 + conA 502.00 
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Table A10,  continued. 
Pooled Sample #31 534.00  PS #34 + conA 426.00 
Pooled Sample #32 292.00  PS #35 + conA 393.00 
Pooled Sample #33 332.00  PS #36 + conA 472.00 
Pooled Sample #34 495.00  PS #37 + conA 395.00 
Pooled Sample #35 371.00  PS #38 + conA 465.00 
Pooled Sample #36 455.00  PS #39 + conA 415.00 
Pooled Sample #37 346.00  PS #40 + conA 440.00 
Pooled Sample #38 487.00  PS #41 + conA 425.00 
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Table A11.  Results for spleen cell proliferation assay with either 10 µL or 20 µL of 
sample. 
 
 
10 µL Sample 20 µL Sample 
Well Contents CPM CPM 
Resting 2,059.00 2,792.00 
Resting 2,963.00 3,062.00 
Resting 2,412.00 2,823.00 
2.5 µL 1:10 conA 8,689.00 9,692.00 
2.5 µL 1:10 conA 10,734.00 14,789.00 
2.5 µL 1:10 conA 10,143.00 13,888.00 
Pooled Sample #1 91.00 50.00 
Pooled Sample #2 283.00 82.00 
Pooled Sample #3 3,666.00 4,572.00 
Pooled Sample #4 2,395.00 422.00 
Pooled Sample #5 3,431.00 3,448.00 
Pooled Sample #6 4,052.00 347.00 
Pooled Sample #7 2,470.00 1,638.00 
Pooled Sample #8 2,493.00 1,252.00 
Pooled Sample #9 2,798.00 455.00 
Pooled Sample #10 4,031.00 534.00 
Pooled Sample #11 3,538.00 2,207.00 
Pooled Sample #12 3,315.00 4,255.00 
Pooled Sample #13 4,332.00 3,286.00 
Pooled Sample #14 6,650.00 9,170.00 
Pooled Sample #15 4,408.00 5,388.00 
Pooled Sample #16 8,505.00 13,715.00 
Pooled Sample #17 6,197.00 7,148.00 
Pooled Sample #18 3,253.00 3,647.00 
Pooled Sample #19 3,071.00 2,104.00 
Pooled Sample #20 3,552.00 2,905.00 
Pooled Sample #21 2,426.00 1,114.00 
Pooled Sample #22 6,631.00 11,355.00 
Pooled Sample #23 1,289.00 198.00 
Pooled Sample #24 5,760.00 10,049.00 
Pooled Sample #25 7,357.00 9,789.00 
Pooled Sample #26 2,921.00 1,510.00 
Pooled Sample #27 539.00 95.00 
Pooled Sample #28 74.00 78.00 
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Table A11,  continued. 
Pooled Sample #29 6,843.00 7,958.00 
Pooled Sample #30 154.00 307.00 
Pooled Sample #31 192.00 79.00 
Pooled Sample #32 4,549.00 4,535.00 
Pooled Sample #33 3,155.00 2,281.00 
Pooled Sample #34 3,213.00 1,318.00 
Pooled Sample #35 2,634.00 514.00 
Pooled Sample #36 1,763.00 926.00 
Pooled Sample #37 2,467.00 1,467.00 
Pooled Sample #38 3,798.00 3,039.00 
Pooled Sample #39 448.00 117.00 
Pooled Sample #40 1,210.00 85.00 
Pooled Sample #41 3,028.00 390.00 
PS #1 + conA 43.00 78.00 
PS #2 + conA 51.00 33.00 
PS #3 + conA 7,002.00 2,792.00 
PS #4 + conA 6,970.00 757.00 
PS #5 + conA 9,259.00 7,727.00 
PS #6 + conA 7,801.00 5,020.00 
PS #7 + conA 6,819.00 1,401.00 
PS #8 + conA 6,414.00 1,665.00 
PS #9 + conA 5,178.00 163.00 
PS #10 + conA 7,418.00 999.00 
PS #11 + conA 4,060.00 2,270.00 
PS #12 + conA 6,428.00 5,431.00 
PS #13 + conA 9,406.00 3,800.00 
PS #14 + conA 15,394.00 17,635.00 
PS #15 + conA 10,676.00 9,066.00 
PS #16 + conA 16,108.00 23,236.00 
PS #17 + conA 12,333.00 14,933.00 
PS #18 + conA 6,971.00 6,942.00 
PS #19 + conA 8,961.00 7,677.00 
PS #20 + conA 10,478.00 6,722.00 
PS #21 + conA 4,763.00 1,314.00 
PS #22 + conA 12,579.00 18,312.00 
PS #23 + conA 2,274.00 272.00 
PS #24 + conA 13,684.00 30,985.00 
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Table A11,  continued. 
PS #25 + conA 16,650.00 1,833.00 
PS #26 + conA 2,794.00 70.00 
PS #27 + conA 649.00 66.00 
PS #28 + conA 247.00 16,463.00 
PS #29 + conA 15,226.00 63.00 
PS #30 + conA 559.00 62.00 
PS #31 + conA 232.00 17,927.00 
PS #32 + conA 15,464.00 7,090.00 
PS #33 + conA 7,698.00 4,303.00 
PS #34 + conA 8,434.00 3,408.00 
PS #35 + conA 5,771.00 1,489.00 
PS #36 + conA 7,172.00 641.00 
PS #37 + conA 7,178.00 2,050.00 
PS #38 + conA 8,036.00 61.00 
PS #39 + conA 352.00 89.00 
PS #40 + conA 2,169.00 872.00 
PS #41 + conA 5,937.00 870.00 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
Table A12.  Results for spleen cell proliferation assay with either 10 µL or 20 µL of 
sample. 
 
 
10 µL Sample 20 µL Sample 
Well Contents CPM CPM 
Resting 691.00 1,463.00 
Resting 1,124.00 2,218.00 
Resting 1,152.00 1,288.00 
2.5 µL 1:10 conA 8,490.00 16,280.00 
2.5 µL 1:10 conA 13,798.00 16,853.00 
2.5 µL 1:10 conA 16,358.00 17,172.00 
Pooled Sample #1 171.00 54.00 
Pooled Sample #2 140.00 58.00 
Pooled Sample #3 980.00 263.00 
Pooled Sample #4 943.00 108.00 
Pooled Sample #5 2,344.00 1,055.00 
Pooled Sample #6 1,303.00 881.00 
Pooled Sample #7 941.00 186.00 
Pooled Sample #8 1,457.00 391.00 
Pooled Sample #9 906.00 142.00 
Pooled Sample #10 1,275.00 246.00 
Pooled Sample #11 1,241.00 481.00 
Pooled Sample #12 2,558.00 1,381.00 
Pooled Sample #13 2,460.00 1,268.00 
Pooled Sample #14 3,221.00 3,836.00 
Pooled Sample #15 4,458.00 1,421.00 
Pooled Sample #16 3,849.00 2,256.00 
Pooled Sample #17 3,739.00 2,141.00 
Pooled Sample #18 2,625.00 1,595.00 
Pooled Sample #19 3,876.00 687.00 
Pooled Sample #20 3,387.00 923.00 
Pooled Sample #21 2,656.00 310.00 
Pooled Sample #22 4,003.00 3,135.00 
Pooled Sample #23 1,161.00 223.00 
Pooled Sample #24 3,147.00 3,235.00 
Pooled Sample #25 2,320.00 2,609.00 
Pooled Sample #26 1,632.00 521.00 
Pooled Sample #27 553.00 130.00 
Pooled Sample #28 323.00 255.00 
48 
 
Table A12,  continued. 
Pooled Sample #29 3,828.00 2,150.00 
Pooled Sample #30 231.00 69.00 
Pooled Sample #31 972.00 121.00 
Pooled Sample #32 3,371.00 4,031.00 
Pooled Sample #33 2,693.00 1,424.00 
Pooled Sample #34 5,839.00 788.00 
Pooled Sample #35 1,415.00 311.00 
Pooled Sample #36 1,331.00 303.00 
Pooled Sample #37 2,601.00 589.00 
Pooled Sample #38 3,097.00 596.00 
Pooled Sample #39 232.00 66.00 
Pooled Sample #40 722.00 115.00 
Pooled Sample #41 1,289.00 161.00 
PS #1 + conA 357.00 1,202.00 
PS #2 + conA 246.00 75.00 
PS #3 + conA 10,536.00 1,577.00 
PS #4 + conA 8,740.00 268.00 
PS #5 + conA 19,597.00 12,351.00 
PS #6 + conA 13,685.00 5,349.00 
PS #7 + conA 6,509.00 1,127.00 
PS #8 + conA 7,756.00 2,345.00 
PS #9 + conA 8,110.00 128.00 
PS #10 + conA 10,876.00 1,366.00 
PS #11 + conA 11,337.00 3,797.00 
PS #12 + conA 16,719.00 6,404.00 
PS #13 + conA 19,613.00 9,202.00 
PS #14 + conA 17,700.00 16,230.00 
PS #15 + conA 14,901.00 11,444.00 
PS #16 + conA 31,467.00 18,999.00 
PS #17 + conA 16,843.00 15,853.00 
PS #18 + conA 11,143.00 6,729.00 
PS #19 + conA 22,316.00 7,133.00 
PS #20 + conA 15,326.00 6,758.00 
PS #21 + conA 13,190.00 1,099.00 
PS #22 + conA 29,887.00 14,137.00 
PS #23 + conA 5,760.00 324.00 
PS #24 + conA 23,123.00 12,561.00 
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Table A12,  continued. 
PS #25 + conA 23,407.00 13,286.00 
PS #26 + conA 9,460.00 2,011.00 
PS #27 + conA 1,802.00 109.00 
PS #28 + conA 176.00 72.00 
PS #29 + conA 19,646.00 15,133.00 
PS #30 + conA 814.00 91.00 
PS #31 + conA 1,150.00 65.00 
PS #32 + conA 22,482.00 18,525.00 
PS #33 + conA 12,880.00 7,612.00 
PS #34 + conA 15,019.00 5,309.00 
PS #35 + conA 11,120.00 1,454.00 
PS #36 + conA 6,757.00 741.00 
PS #37 + conA 11,383.00 4,318.00 
PS #38 + conA 11,083.00 6,437.00 
PS #39 + conA 1,174.00 117.00 
PS #40 + conA 4,208.00 129.00 
PS #41 + conA 6,817.00 335.00 
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Table A13.  Results for tumor cell proliferation assay with either 10 µL or 20 µL of 
sample. 
 
 
10 μL sample 20 μL sample 
Well Contents CPM CPM 
5 µL cells 133,865 
5 µL cells + Sample #1 7,772 98 
5 µL cells + Sample #2 942 113 
5 µL cells + Sample #3 99,781 9,149 
5 µL cells + Sample #4 76,550 6,927 
5 µL cells + Sample #5 92,439 61,373 
5 µL cells + Sample #6 68,532 40,153 
5 µL cells + Sample #7 49,940 14,029 
5 µL cells + Sample #8 47,981 28,220 
5 µL cells + Sample #9 37,102 566 
5 µL cells + Sample #10 51,538 3,896 
5 µL cells + Sample #11 50,241 10,673 
5 µL cells + Sample #12 89,222 30,584 
5 µL cells + Sample #13 78,424 24,265 
5 µL cells + Sample #14 104,938 56,777 
5 µL cells + Sample #15 98,336 37,278 
5 µL cells + Sample #16 128,217 55,428 
5 µL cells + Sample #17 106,168 52,356 
5 µL cells + Sample #18 83,032 36,893 
5 µL cells + Sample #19 78,356 26,885 
5 µL cells + Sample #20 71,534 28,370 
5 µL cells + Sample #21 43,152 508 
5 µL cells + Sample #22 124,830 96,028 
5 µL cells + Sample #23 18,586 4937 
5 µL cells + Sample #24 75,868 44364 
5 µL cells + Sample #25 116,613 67,067 
5 µL cells + Sample #26 41,864 1,272 
5 µL cells + Sample #27 13,132 2,780 
5 µL cells + Sample #28 8,934 697 
5 µL cells + Sample #29 83,238 59,730 
5 µL cells + Sample #30 19,231 7,166 
5 µL cells + Sample #31 17,839 3,284 
5 µL cells + Sample #32 123,049 100,528 
5 µL cells + Sample #33 81,110 70,606 
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Table A13,  continued. 
5 µL cells + Sample #34 26,647 65,098 
5 µL cells + Sample #35 73,889 10,960 
5 µL cells + Sample #36 54,560 553 
5 µL cells + Sample #37 97,206 58,584 
5 µL cells + Sample #38 69,957 5,181 
5 µL cells + Sample #39 10,163 2,409 
5 µL cells + Sample #40 24,757 4,676 
5 µL cells + Sample #41 31,644 12,125 
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Table A14.  Results for tumor cell proliferation assay with either 10 µL or 20 µL of 
sample. 
 
 
10 μL sample 20 μL sample 
Well Contents CPM CPM 
5 µL cells 46,485 
5 µL cells + PBS 35,452 
5 µL cells + Sample #1 152 80 
5 µL cells + Sample #2 371 69 
5 µL cells + Sample #3 18,187 685 
5 µL cells + Sample #4 23,636 262 
5 µL cells + Sample #5 27,957 30,214 
5 µL cells + Sample #6 23,192 1,897 
5 µL cells + Sample #7 14,752 2,781 
5 µL cells + Sample #8 14,274 7,377 
5 µL cells + Sample #9 6,457 193 
5 µL cells + Sample #10 20,695 5,360 
5 µL cells + Sample #11 14,607 1,131 
5 µL cells + Sample #12 22,893 4,592 
5 µL cells + Sample #13 13,560 10,303 
5 µL cells + Sample #14 33,748 8,689 
5 µL cells + Sample #15 23,337 10,062 
5 µL cells + Sample #16 51,454 11,901 
5 µL cells + Sample #17 37,253 376 
5 µL cells + Sample #18 39,032 143 
5 µL cells + Sample #19 17,538 8,579 
5 µL cells + Sample #20 45,723 5,116 
5 µL cells + Sample #21 5,442 129 
5 µL cells + Sample #22 53,690 1,930 
5 µL cells + Sample #23 7,052 955 
5 µL cells + Sample #24 44,288 5,255 
5 µL cells + Sample #25 69,288 13,180 
5 µL cells + Sample #26 8,620 110 
5 µL cells + Sample #27 7,140 164 
5 µL cells + Sample #28 670 179 
5 µL cells + Sample #29 74,205 147 
5 µL cells + Sample #30 3,936 154 
5 µL cells + Sample #31 7,177 119 
5 µL cells + Sample #32 69,740 130 
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Table A14,  continued. 
5 µL cells + Sample #33 44,165 736 
5 µL cells + Sample #34 78,044 14,622 
5 µL cells + Sample #35 39,939 30,921 
5 µL cells + Sample #36 52,412 124 
5 µL cells + Sample #37 67,633 193 
5 µL cells + Sample #38 31,563 159 
5 µL cells + Sample #39 11,014 143 
5 µL cells + Sample #40 26,231 7,322 
5 µL cells + Sample #41 22,466 168 
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Table A15.  Results for tumor cell proliferation assay with either 10 µL or 20 µL of 
sample. 
 
 
10 µL Sample 20 µL Sample 
Well Contents CPM CPM 
5 µL cells 6,301 
5 µL cells + PBS 7,198 
5 µL cells + Sample #1 89.00 160.00 
5 µL cells + Sample #2 90.00 127.00 
5 µL cells + Sample #3 192.00 66.00 
5 µL cells + Sample #4 67.00 93.00 
5 µL cells + Sample #5 684.00 134.00 
5 µL cells + Sample #6 382.00 192.00 
5 µL cells + Sample #7 122.00 189.00 
5 µL cells + Sample #8 197.00 285.00 
5 µL cells + Sample #9 116.00 173.00 
5 µL cells + Sample #10 450.00 103.00 
5 µL cells + Sample #11 281.00 298.00 
5 µL cells + Sample #12 504.00 233.00 
5 µL cells + Sample #13 793.00 277.00 
5 µL cells + Sample #14 7,734.00 4,746.00 
5 µL cells + Sample #15 3,151.00 516.00 
5 µL cells + Sample #16 8,089.00 881.00 
5 µL cells + Sample #17 3,697.00 894.00 
5 µL cells + Sample #18 518.00 276.00 
5 µL cells + Sample #19 510.00 172.00 
5 µL cells + Sample #20 4,103.00 158.00 
5 µL cells + Sample #21 761.00 76.00 
5 µL cells + Sample #22 6,402.00 4,154.00 
5 µL cells + Sample #23 179.00 85.00 
5 µL cells + Sample #24 5,270.00 3230.00 
5 µL cells + Sample #25 6,454.00 2,737.00 
5 µL cells + Sample #26 215.00 93.00 
5 µL cells + Sample #27 159.00 110.00 
5 µL cells + Sample #28 488.00 155.00 
5 µL cells + Sample #29 7,258.00 3,733.00 
5 µL cells + Sample #30 807.00 136.00 
5 µL cells + Sample #31 1,063.00 149.00 
5 µL cells + Sample #32 7,308.00 4,891.00 
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Table A15,  continued. 
5 µL cells + Sample #33 1,281.00 214.00 
5 µL cells + Sample #34 540.00 188.00 
5 µL cells + Sample #35 1,534.00 127.00 
5 µL cells + Sample #36 479.00 157.00 
5 µL cells + Sample #37 657.00 206.00 
5 µL cells + Sample #38 405.00 157.00 
5 µL cells + Sample #39 132.00 168.00 
5 µL cells + Sample #40 354.00 182.00 
5 µL cells + Sample #41 124.00 138.00 
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Table A16.  Results for caspase 8 assay with tumor cells and select samples. 
 
Well Contents 
pNA (nmol/min/mL) 
after 24 hours 
pNA (nmol/min/mL) 
after 48 hours 
Reagent Blank 0.090  
+ Control 9.525  
5 µL cells 0.023 0.791 
5 µL cells + Sample #1 1.808 -2.667 
5 µL cells + Sample #2 0.226 1.379 
5 µL cells + Sample #7 0.249 0.090 
5 µL cells + Sample #8 0.090 0.000 
5 µL cells + Sample #9 0.407 -0.068 
5 µL cells + Sample #10 -0.068 1.469 
5 µL cells + Sample #11 1.175 0.158 
5 µL cells + Sample #21 0.000 -0.927 
5 µL cells + Sample #23 0.158 3.232 
5 µL cells + Sample #26 4.497 1.469 
5 µL cells + Sample #27 0.973 0.475 
5 µL cells + Sample #28 0.723 3.028 
5 µL cells + Sample #30 -0.520 0.746 
5 µL cells + Sample #31 5.153 1.107 
5 µL cells + Sample #34 0.610 1.266 
5 µL cells + Sample #36 2.780 1.266 
5 µL cells + Sample #39 3.503 -0.023 
5 µL cells + Sample #40 -0.023 0.814 
5 µL cells + Sample #41 -0.158 12.972 
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Appendix B:  Figures 
 
 
 
 
 
 
 
     
 
Figure B1.  Collection of samples resolved through column chromatography (a,b). 
 
 
 
 
 
 
 
 
a. b. 
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Figure B2.  Evaporation techniques used to remove solvent (methanol). (a) Rotary 
evaporation and (b) Centrifugation with a vacuum pump. 
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b. 
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Figure B3.  Cell harvesting. (a) Washing of the wells with PBS and (b) Removal of the 
filter discs. 
 
 
 
 
 
 
 
 
 
b. 
a. 
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Figure B4.  Spleen cell proliferation with 10 μL sample. (a) 2.5 μL 1:10 concanavalin A  
(b) 2.5 μL 1:10 concanavalin A + sample #19 (c) 2.5 μL 1:10 concanavalin A + sample 
#32. 
 
a. 
b. 
c. 
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Figure B5.  Spleen cell proliferation with 20 μL sample. (a) 2.5 μL 1:10 concanavalin A 
(b) 2.5 μL 1:10 concanavalin A + sample #17 (c) 2.5 μL 1:10 concanavalin A + sample 
#31. 
 
a. 
b. 
c. 
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Figure B6.  Tumor cell proliferation with 10 μL sample. (a) Control (b) + PBS (c) + 
sample #16 (d) + sample #27. 
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Figure B7.  Tumor cell proliferation with 20 µL sample. (a) Control (b) + PBS (c) + 
sample #7 (d) + sample #11. 
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Figure B8.  Apoptosis pathway. 
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Figure B9.  The results of the spleen cell proliferation assay conducted with all resolved 
samples through column chromatography. 
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Figure B10.  The results of a spleen cell proliferation assay conducted with 1:2 dilution of 
methanol. 
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Figure B11.  The results of a spleen cell proliferation assay conducted with the mobile 
phase used for column chromatography. 
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Figure B12.  The results of a spleen cell proliferation assay conducted with dialyzed and 
fully evaporated samples. 
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Figure B13.  The combined results of spleen cell proliferation assays conducted with 10 
μL of the samples dried through centrifugation with a vacuum pump. 
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Figure B14.  The combined results of spleen cell proliferation assays conducted with 20 
μL of the samples dried through centrifugation with a vacuum pump. 
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Figure B15.  The combined results of tumor cell proliferation assays conducted with 10 
μL of the samples dried through centrifugation with a vacuum pump. 
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Figure B16.  The combined results of tumor cell proliferation assays conducted with 20 
μL of the samples dried through centrifugation with a vacuum pump. 
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Appendix C:  Solution Recipes 
 
Column Chromatography Mobile Phase (Silica Gel as the Stationary Phase) 
The designated mobile phase for this procedure was a mixture of 200mL ethyl 
acetate, 22mL formic acid, 22 mL acetic acid, and 52 mL deionized water. The mixture 
was shaken rigorously due to the immiscible nature of the chemicals and poured through 
the column. 
 
Column Chromatography Mobile Phase (nPVP as the Stationary Phase) 
The mobile phase was prepared through the combination of varying mixtures of 
methanol and water with a consistent amount of 0.01N HCl. 150 mL of each solution was 
poured through the column. 
1:   0% MeOH:  500-mL H2O + 50-mL 0.01N HCl 
2:   10% MeOH:  50-mL MeOH + 450-mL H2O + 50-mL 0.01N HCl 
3:   20% MeOH:  100-mL MeOH + 400-mL H2O + 50-mL 0.01N HCl 
4:   30% MeOH:  150-mL MeOH + 350-mL H2O + 50-mL 0.01N HCl 
5:   40% MeOH:  200-mL MeOH + 300-mL H2O + 50-mL 0.01N HCl 
6:   50% MeOH:  250-mL MeOH + 250-mL H2O + 50-mL 0.01N HCl 
7:   60% MeOH:  300-mL MeOH + 200-mL H2O + 50-mL 0.01N HCl 
8:   70% MeOH:  350-mL MeOH + 150-mL H2O + 50-mL 0.01N HCl 
9:   80% MeOH:  400-mL MeOH + 100-mL H2O + 50-mL 0.01N HCl 
10: 90% MeOH:  450-mL MeOH + 50-mL H2O + 50-mL 0.01N HCl 
11: 100% MeOH:  500-mL MeOH + 50-mL 0.01N HCl 
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RPMI-1640 Nutrient Media (Used for Spleen Cell Culture) 
Add one jar of RMPI-1640 to 1 liter of deionized water. To this, add 2.0g sodium 
bicarbonate, and 10 mL of penicillin-streptomycin. Filter-sterilize the media using a 
vacuum filtration technique. 
 
Eagle MEM X Nutrient Media (Used for the Mewo Cell Culture) 
10 mL PSG (antibiotic + L-glutamine), 5 mL NEAA (non-essential amino acid 
solution), and 0.5 mL Ampho-Beta antifungal were added to one bottle of Eagle MEM 
1X media (500-mL), The reagents were mixed by gently inverting the bottle. 
 
 
 
